Danaher to Acquire the Biopharma Business of General Electric Life Sciences for $21.4 Billion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Danaher (DHR) PT Raised to $125 at Baird
February 26, 2019 9:15 AM ESTBaird analyst Richard Eastman raised the price target on Danaher (NYSE: DHR) to $125.00 (from $114.00) while maintaining an Outperform rating following the announced GE Biopharma acquisition. Eastman views the acquisition as attractive.
Adjusting for ~$1.4B in NPV tax benefits to DHR, the purchase price... More
General Electric (GE) Adds to Gains Following BioPharma Deal, Up 18%
February 25, 2019 8:09 AM ESTGeneral Electric (NYSE: GE) Adds to Gains Following BioPharma Deal, Up 18%
... MoreGeneral Electric (GE) Jumps 7% on BioPharma Sale
February 25, 2019 7:13 AM ESTGeneral Electric (NYSE: GE) gains 7% after selling is BioPharma Business to Danaher (DHR) for $21.4 billion.
... More